Post-Market Clinical Follow-up (PMCF) Study to Evaluate Safety and Performance of the DUO Venous Stent

Study Overview
=================
Brief Summary
-----------------
This observational study is to evaluate performance and safety of the DUO Venous Stent for the treatment of obstructions of the iliac vein.

Official Title
-----------------
Prospective, Single-centre Post-Market Clinical Follow-up (PMCF) Study to Evaluate Safety and Performance of the DUO Venous Stent

Conditions
-----------------
Deep Venous Obstructions

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is willing and able to provide inform consent Patients must be ≥ 18 years of age at the time of consent Estimated life expectancy ≥ 12 months. Body mass index (BMI) <35 Patients to whom the DUO Venous Stent can be implanted according to the IFU (this includes acute iliac deep vein thrombosis (DVT), post-thrombotic syndrome, non-thrombotic iliac vein compression (e.g. May-Thurner), non-thrombotic iliac vein compression (e.g. compression from ecstatic or tortuous iliac arteries)) As per IFU, clinically significant symptomatic venous outflow obstruction in the iliac venous segment, associated by at least one of the following: CEAP score ≥3 VCSS pain score ≥2 Subject is willing and able to comply with physician's recommendation for compression therapy - Exclusion Criteria: Presence or history of clinically significant pulmonary emboli within 180 days prior to enrolment. Uncontrolled or active coagulopathy or known, incorrectable bleeding diathesis Prior surgical or endovascular procedure of the target vessel except for catheter-directed or mechanical thrombolysis for DVT within 90 days prior to the index procedure or prior venoplasty Planned surgical or interventional procedures of the target limb (except thrombolysis and/or thrombectomy in preparation for the procedure or vena cava filter placement prior to stent implantation in patients at high risk for pulmonary embolism) within 30 days prior to or 30 days after the index procedure Previous stenting of the target vessel Combination of stents from different manufacturers Participation in another investigational study in which the subject has not completed all primary endpoints or which involves any investigational drug or device that may potentially confound the results of the study Other comorbidities that, in the opinion of the investigator, would preclude the patient from receiving this treatment and/or participating in study-required follow-up assessments Women who are pregnant or lactating Suspected alcohol or drug abuse Patients with any contraindications as mentioned in the Instructions for Use (IFU) of the study device.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary patency rate at month 12 | The primary patency rate is defined as the percentage of stented target lesions with primary treatment success and without the occurrence of thrombosis of the treated lesion or any re-intervention (surgical interventions on the target vessel) to restore or maintain flow within the treated lesion | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary patency rates |  | 30 Days, 6 and 24 months | 
| Secondary patency rates | Percentage of patients with primary treatment success and without occurrence of permanent loss of flow in the treated segment, irrespective of any reintervention | 30 Days, 6, 12 and 24 months | 
| Revised Venous Clinical Severity Score (VCSS) | The score includes 10 clinical parameters (pain, varicose veins, venous edema, skin hyperpigmentation, inflammation, induration, number of ulcers, durations of ulcers, size of ulcers, and compliance with compression therapy). Each item is graded from zero to three depending on severity (None = 0, Mild = 1, Moderate = 2, Severe = 3). | 30 Days 6, 12 and 24 month | 
| Clinical Etiological Anatomical Pathophysiological Classification score (CEAP) | The score for the clinical condition of the chronic venous insufficiency (C0 to C6) will be evaluated whereas C0 is representing the best and C6 the worst condition | 30 Days, 6, 12 and 24 months | 
| Villalta score | The score includes five symptoms (pain, cramps, heaviness, paresthesia, pruritus) and six clinical signs (pretibial edema, skin induration, hyperpigmentation, redness, venous ectasia, pain on calf compression).Each item is graded from zero (not present)to three (severe). | 30 Days, 6, 12 and 24 month | 
| Device or procedure-related adverse events |  | 30 Days, 6, 12 and 24 month | 
| Serious adverse events |  | 30 Days, 6, 12 and 24 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Venous stent system